Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease a retrospective observational cohort study with a systematic literature review

Journal of Thoracic Oncology

Volumn 10, Issue 8, 2015, Pages 1148-1155

  Créquit, Perrine ^a   Wislez, Marie ^b   Feith, Jocelyne Fleury ^a   Rozensztajn, Nathalie ^d   Jabot, Laurence ^a   Friard, Sylvie ^a   Lavole, Armelle ^a   Gounant, Valérie ^a   Fillon, Julie ^c   Antoine, Martine ^a   Cadranel, Jacques ^a  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d FOCH HOSPITAL   (France)

Author keywords

Crizotinib; Echinoderm microtubule associated protein like 4 anaplastic lymphoma kinase; Interstitial lung disease; Non small cell lung cancer.

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; DIURETIC AGENT; FLUORODEOXYGLUCOSE; PACLITAXEL; PREDNISONE; ANAPLASTIC LYMPHOMA KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVERSE DRUG REACTION; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; CRACKLE; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GROUND GLASS OPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG LAVAGE; LUNG TOXICITY; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHOTON EMISSION TOMOGRAPHY; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CASE REPORT; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84942869017     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000577     Document Type: Article

References (34)

1. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10, 000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013;31:abstr 8000
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703
3. Crin L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29:abstr 7514
4. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394
5. Solomon BJ, Mok T, Kim DW, et al; PROFILE 1014 Investigators. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-2177
6. EMA. Pfizer Limited. Xalkori 200 mg hard capsules: EU summary of product characteristics. 2012. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/EPARProduct-Information/human/002489/WC500134759.pdf. Accessed May 1, 2014
7. U.S. Food and Drug Administration. [FDA homepage] Label approved on 11/20/2013 (PDF) for XALKORI, NDA no. 202570. Reference ID: 3410361, para 5.2, p. 4. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/202570s006lbl.pdf. Accessed February 2, 2015
8. Sakai F, Johkoh T, Kusumoto M, Arakawa H, Takahashi M. Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings. Int J Clin Oncol 2012;17:542-550
9. Austin JH, Mller NL, Friedman PJ, et al. Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996;200:327-331
10. Ono A, Takahashi T, Oishi T, et al. Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. J Clin Oncol 2013;31:e417-e419
11. Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol 2013;31:e15-e17
12. Yanagisawa S, Inoue A, Koarai A, Ono M, Tamai T, Ichinose M. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease. J Thorac Oncol 2013;8:e73-e74
13. Andarini S, Sahli F, Pangestu H. Severe acute interstitial lung disease in EML4-ALK-Positive non-small cell lung cancer treated with crizotinib. Respirology 2014;19:145-153
14. Asai N, Yamaguchi E, Kubo A. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced nonsmall-cell lung cancer. Clin Lung Cancer 2014;15:e33-e35
15. Ji Y, Zhang Z, Nie K, et al. Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer. Chin Med J (Engl) 2014;127:1600
16. Maka VV, Krishnaswamy UM, Kumar NA, et al. Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-smallcell lung cancer after crizotinib therapy Disponible sur. Available at: http://omcr.oxfordjournals.org. Accessed February 11, 2015
17. Tachihara M, Kobayashi K, Ishikawa Y, et al. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease. Jpn J Clin Oncol 2014;44:762-764
18. Watanabe N, Nakahara Y, Taniguchi H, et al. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia. Acta Oncol 2014;53:158-160
19. Park J, Yamaura H, Yatabe Y, et al. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med 2014;3:118-123
20. Doebele RC, Lu X, Sumey C, et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012;118:4502-4511
21. Fallet V, Cadranel J, Doubre H, et al. Prospective screening for ALK: clinical features and outcome according to ALK status. Eur J Cancer 2014;50:1239-1246
22. Behr J. Approach to the diagnosis of interstitial lung disease. Clin Chest Med 2012;33:1-10
23. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007;1108:166-182
24. Grunes D, Beasley MB. Hypersensitivity pneumonitis: a review and update of histologic findings. J Clin Pathol 2013;66:888-895
25. De Sanctis A, Taillade L, Vignot S, et al. Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. Cancer 2011;117:3069-3080
26. Saito Y, Gemma A. Current status of DILD in molecular targeted therapies. Int J Clin Oncol 2012;17:534-541
27. Fuhrman C, Parrot A, Wislez M, et al. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis. Am J Respir Crit Care Med 2001;164:1186-1191
28. Liot H, Liot F, Sroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010;35:681-687
29. Albiges L, Chammings F, Duclos B, et al. Incidence and management of mTOR inhibitor-Associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:1943-1953
30. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-Analysis of clinical trials. Lung Cancer 2014;83:231-239
31. Ait-Tahar K, Cerundolo V, Banham AH, et al. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer 2006;118:688-695
32. Passoni L, Gallo B, Biganzoli E, et al. In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas. Haematologica 2006;91:48-55
33. Ait-Tahar K, Damm-Welk C, Burkhardt B, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010;115:3314-3319
34. Mussolin L, Damm-Welk C, Pillon M, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia 2013;27:416-422